FR2322601A1
(fr)
*
|
1975-09-04 |
1977-04-01 |
Rhone Poulenc Ind |
Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
|
AR208414A1
(es)
*
|
1974-11-07 |
1976-12-27 |
Rhone Poulenc Ind |
Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
|
JPS5680585A
(en)
*
|
1979-11-30 |
1981-07-01 |
Toyoda Gosei Kk |
High pressure hose
|
JPS57144860A
(en)
*
|
1981-03-04 |
1982-09-07 |
Matsushita Electric Ind Co Ltd |
Secondary side water pressure controller for water cooler
|
DE3378763D1
(en)
*
|
1982-04-02 |
1989-02-02 |
Takeda Chemical Industries Ltd |
Condensed pyrrolinone derivatives, and their production
|
JPS6169773A
(ja)
*
|
1984-09-14 |
1986-04-10 |
Takeda Chem Ind Ltd |
イソインドリノン誘導体
|
JPS6297400U
(nl)
*
|
1985-12-09 |
1987-06-20 |
|
|
FR2607504B1
(fr)
*
|
1986-12-02 |
1989-01-27 |
Rhone Poulenc Sante |
Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2671800B1
(fr)
*
|
1991-01-17 |
1993-03-12 |
Rhone Poulenc Rorer Sa |
Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
|
WO1993010787A1
(en)
*
|
1991-12-02 |
1993-06-10 |
Sepracor, Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
|
WO1993010788A1
(en)
*
|
1991-12-02 |
1993-06-10 |
Sepracor, Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
|
US5786357A
(en)
*
|
1991-12-02 |
1998-07-28 |
Sepracor Inc. |
Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
|
CN1206996C
(zh)
|
1998-06-09 |
2005-06-22 |
武田药品工业株式会社 |
用于治疗或预防睡眠障碍的药物组合物
|
US6339086B1
(en)
|
1999-05-14 |
2002-01-15 |
Swpracor, Inc. |
Methods of making and using N-desmethylzopiclone
|
ES2203319B1
(es)
*
|
2002-04-03 |
2005-03-01 |
Universidad De Oviedo |
Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
|
WO2005060968A1
(en)
|
2003-12-11 |
2005-07-07 |
Sepracor Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
CN101257898A
(zh)
*
|
2005-07-06 |
2008-09-03 |
塞普拉科公司 |
艾司佐匹克隆与o-去甲基文拉法辛的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
|
WO2007006003A2
(en)
|
2005-07-06 |
2007-01-11 |
Sepracor Inc. |
Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
US7476737B2
(en)
*
|
2005-09-05 |
2009-01-13 |
Dr. Reddy's Laboratories Limited |
Eszopiclone process
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
US20070112017A1
(en)
*
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
AR059296A1
(es)
*
|
2006-02-03 |
2008-03-26 |
Synthon Bv |
Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona.
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007109799A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
JP2008543953A
(ja)
*
|
2006-04-20 |
2008-12-04 |
テバ ファーマシューティカル インダストリーズ リミティド |
エスゾピクロン結晶形態a、実質的に純粋なエスゾピクロン及び光学的に豊富なエスゾピクロンを調製するための方法
|
CN101058581B
(zh)
*
|
2006-04-21 |
2011-06-08 |
天津天士力集团有限公司 |
右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
EP2026813A2
(en)
*
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US20080015197A1
(en)
*
|
2006-06-26 |
2008-01-17 |
Alex Mainfeld |
Process for the preparatrion of zopiclone
|
JP2010502722A
(ja)
*
|
2006-09-08 |
2010-01-28 |
ブレインセルス,インコーポレイティド |
4−アシルアミノピリジン誘導体を含む組み合わせ
|
CA2663347A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
US7786304B2
(en)
*
|
2006-11-06 |
2010-08-31 |
Centaur Pharmaceutical Pvt. Ltd. |
Process for the preparation of eszopiclone
|
EP2032557A2
(en)
*
|
2007-01-31 |
2009-03-11 |
Teva Pharmaceutical Industries Ltd. |
Methods for preparing eszopiclone
|
US20080305171A1
(en)
*
|
2007-06-07 |
2008-12-11 |
Kristin Anne Arnold |
Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
|
US20090018336A1
(en)
*
|
2007-06-25 |
2009-01-15 |
Nina Finkelstein |
Racemization process of R-zopiclone
|
EP2020403A1
(en)
|
2007-08-02 |
2009-02-04 |
Esteve Quimica, S.A. |
Process for the resolution of zopiclone and intermediate compounds
|
US20090198058A1
(en)
*
|
2007-08-06 |
2009-08-06 |
Dhananjay Govind Sathe |
Process for Preparation of Dextrorotatory Isomer of 6-(5- chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone)
|
US20100190797A1
(en)
*
|
2007-12-11 |
2010-07-29 |
Cipla Ltd. |
Crystalline polymophic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
|
US8198278B2
(en)
*
|
2007-12-19 |
2012-06-12 |
Sunovion Pharmaceuticals Inc. |
Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
CN100467471C
(zh)
*
|
2007-12-19 |
2009-03-11 |
齐鲁天和惠世制药有限公司 |
佐匹克隆的制备方法
|
US8212036B2
(en)
*
|
2007-12-19 |
2012-07-03 |
Sunovion Pharmaceuticals Inc. |
Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8198277B2
(en)
|
2007-12-19 |
2012-06-12 |
Sunovion Pharmaceuticals Inc. |
L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8268832B2
(en)
*
|
2007-12-19 |
2012-09-18 |
Sunovion Pharmaceuticals Inc. |
Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US8269005B2
(en)
*
|
2007-12-19 |
2012-09-18 |
Sunovion Pharmaceuticals Inc. |
L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
|
US20110053945A1
(en)
*
|
2007-12-19 |
2011-03-03 |
Sepracor Inc. |
Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
|
CA2812705C
(en)
*
|
2007-12-19 |
2015-08-18 |
Sunovion Pharmaceuticals Inc. |
Maleate, besylate and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
|
US20100221338A1
(en)
|
2009-01-30 |
2010-09-02 |
Sepracor Inc. |
Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of Coating
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
CN105399745A
(zh)
*
|
2015-12-17 |
2016-03-16 |
天津华津制药有限公司 |
一种吡嗪并羟基吡咯烷酮类化合物的制备方法
|
US11547706B2
(en)
|
2016-06-08 |
2023-01-10 |
President And Fellows Of Harvard College |
Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome
|
CN106220630B
(zh)
*
|
2016-07-23 |
2019-12-10 |
迪嘉药业集团有限公司 |
一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
|
EP3801512A4
(en)
|
2018-05-29 |
2022-01-19 |
President and Fellows of Harvard College |
COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
|